Continuous intravenous administration of vancomycin in medical intensive care unit patients
Standard
Continuous intravenous administration of vancomycin in medical intensive care unit patients. / Saugel, Bernd; Nowack, Marisa C M; Hapfelmeier, Alexander; Umgelter, Andreas; Schultheiss, Caroline; Thies, Philipp; Phillip, Veit; Eyer, Florian; Schmid, Roland M; Huber, Wolfgang.
In: J CRIT CARE, Vol. 28, No. 1, 01.02.2013, p. 9-13.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Continuous intravenous administration of vancomycin in medical intensive care unit patients
AU - Saugel, Bernd
AU - Nowack, Marisa C M
AU - Hapfelmeier, Alexander
AU - Umgelter, Andreas
AU - Schultheiss, Caroline
AU - Thies, Philipp
AU - Phillip, Veit
AU - Eyer, Florian
AU - Schmid, Roland M
AU - Huber, Wolfgang
N1 - Copyright © 2013 Elsevier Inc. All rights reserved.
PY - 2013/2/1
Y1 - 2013/2/1
N2 - PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients.MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion.RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041).CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.
AB - PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients.MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion.RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041).CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.
KW - Anti-Bacterial Agents
KW - Area Under Curve
KW - Case-Control Studies
KW - Drug Administration Schedule
KW - Drug Monitoring
KW - Female
KW - Germany
KW - Humans
KW - Infusions, Intravenous
KW - Intensive Care Units
KW - Male
KW - Microbial Sensitivity Tests
KW - Middle Aged
KW - Retrospective Studies
KW - Sepsis
KW - Vancomycin
U2 - 10.1016/j.jcrc.2012.02.003
DO - 10.1016/j.jcrc.2012.02.003
M3 - SCORING: Journal article
C2 - 22459156
VL - 28
SP - 9
EP - 13
JO - J CRIT CARE
JF - J CRIT CARE
SN - 0883-9441
IS - 1
ER -